This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207). For additional information on Bedaquiline, visit our online Global TB Drug Pipeline where there are two projects on Bedaquiline–http://www.newtbdrugs.org/project.php?id=141 and http://www.newtbdrugs.org/project.php?id=125.

Related News Coverage:

J&J’s Janssen unit seeks approval for first medicine against multidrug-resistant tuberculosis (Washington Post)

Janssen Research & Development Submits New Drug Application to FDA for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline (TMC207) (MarketWatch)

Additional TB R&D News:

AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis

Seegene to Introduce Real-Time Multiple Mutation Detection Technology for Drug Resistant Mutations in M. tuberculosis at AACC 2012

Epistem’s TB Assay Achieves CE-IVD Certification

Obama administration closes Global Health Initiative office